#ACR19

Patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitors for malignancy experience severe immune related Adverse Events (irAEs) at a similar rate to other cancer patients without autoimmune diseases. A study of 84 RA patients with cancers such as melanoma and...

Patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitors for malignancy experience severe immune related Adverse Events (irAEs) at a...

Previews of draft guidelines for gout, vasculitis and osteoarthritis were up for discussion at the 2019 ACR/ARP Annual Meeting in Atlanta. The guideline documents, currently under peer review, are scheduled for publication in 2020. Here’s a summary of the some of...

Previews of draft guidelines for gout, vasculitis and osteoarthritis were up for discussion at the 2019 ACR/ARP Annual Meeting in...

Patterns of use for biologics in rheumatoid arthritis are complex, according to Australian research presented at the 2019 ACR/ARP Annual Meeting in Atlanta. According to an analysis of 3,470 participants in ARAD (Australian Rheumatology Association Database) from 2001 to 2018, first-line...

Patterns of use for biologics in rheumatoid arthritis are complex, according to Australian research presented at the 2019 ACR/ARP Annual...